GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
about
K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory ArthritisThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionGM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity.GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease.CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptorsGranulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammationGranulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammationPhase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to dateThe influence of macrophage growth factors on Theiler's Murine Encephalomyelitis Virus (TMEV) infection and activation of macrophages.Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria.Engineered cell migration to lesions linked to autoimmune disease.Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.CCL17 blockade as a therapy for osteoarthritis pain and disease.TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.
P2860
Q26745541-DA3F9182-6D83-4741-B7A6-DB14CED0422AQ28076760-8DD2F59F-AF4E-4159-8AA2-857DF83098ACQ30835058-82BD8DCA-5B50-4D64-AAAC-DF551173F545Q36339061-03150F4A-B01D-4B60-84F7-216DF3F63D24Q37138955-F0F58FF7-49DD-4C2F-A090-423E2B056274Q37217530-0270A6BA-E253-4783-8540-556F0BBDFA16Q37466119-EEFE8B37-B03B-484F-875F-285029BA85D5Q37690033-A54FD8C3-C5CF-43AD-96AA-A60149BFD8E8Q38741139-DB95EA78-BCD9-4C30-B885-D439431B3B16Q38988087-9873019C-5B21-46E3-9E13-A9AC95A2AF10Q40085799-F225E805-3B47-4B56-AB3A-309546974F48Q42372846-254AF914-C817-4690-8350-721B8BE49239Q47240544-52271ED6-DEE7-4B51-B74B-4F4D02360276Q49393096-6C550D58-943D-42D0-BFD2-96BE00B414EBQ52604134-5037D0D1-3A63-405B-BCEC-464410DE3A84Q52644010-8D1EF006-861C-4C11-ADCC-CE5D44FA9976Q55052878-77FFDBDF-AB39-4CE1-BDB3-337BEFA0C6D9
P2860
GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
GM-CSF as a target in inflamma ...... future therapeutic potential.
@en
type
label
GM-CSF as a target in inflamma ...... future therapeutic potential.
@en
prefLabel
GM-CSF as a target in inflamma ...... future therapeutic potential.
@en
P2860
P1476
GM-CSF as a target in inflamma ...... d future therapeutic potential
@en
P2093
John A Hamilton
P2860
P304
P356
10.1586/1744666X.2015.1024110
P577
2015-03-08T00:00:00Z